Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.99983
Revised: September 29, 2024
Accepted: November 18, 2024
Published online: January 21, 2025
Processing time: 137 Days and 14.2 Hours
Liver cancer, and in particular hepatocellular carcinoma (HCC) is a disease of rising prevalence and incidence. To date, definitive treatment options include either surgical excision or ablation of the affected area. With increasing research on several pathways that could be involved in the progression of HCC, new elements within these pathways emerge as potential targets for novel therapies. The WNT/β-catenin pathway favors the presence of M2 tumor-associated macrophages which in turn promote tumor growth and metastasis. The inhibition of this pathway is considered a good candidate for such targeted therapeutic interventions. Interestingly, as Huang et al show in their recently published article, Calculus bovis which is used in traditional Chinese medicine can exert an inhibitory effect on the β-catenin pathway and become a potential candidate for targeted pharmacotherapy against liver cancer.
Core Tip: Activation of the WNT/β-catenin pathway plays an important role in hepatocellular carcinoma (HCC) development and the modulation of the tumor microenvironment through M2 macrophage production. Calculus bovis (CB), an herb used in traditional Chinese medicine, exhibits liver anti-tumor properties: Inhibition of the WNT/β-catenin pathway and subsequent decrease in M2 tumor-associated macrophages polarization. In all, the inhibition of WNT/β-catenin pathway emerges as a therapeutic target while the use of CB surfaces as potential medium to achieve this kind of modulation. CB, therefore, appears to be a lucrative candidate that can aid in the pharmacotherapy of HCC.